查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1608033

Hürthle 细胞癌症治疗市场：按治疗方法、最终用户划分 - 全球预测 2025-2030 年

Hurthle Cell Carcinoma Treatment Market by Treatment (General Surgery, Radioactive Iodine, Robotic Surgery), End User (Ambulatory Surgical Center, Clinic, Hospital) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

Hürthle细胞癌症治疗市场2023年估值为64.4亿美元，预计2024年将达到68.2亿美元，复合年增长率为6.41%，到2030年将达到99.6亿美元。

许特勒细胞癌 (HCC) 是一种罕见的甲状腺癌，约占分化型甲状腺癌的 3% 至 5%。 HCC 研究和治疗的范围包括了解其生物学行为、诊断和有效的治疗方法。对创新治疗方法的需求至关重要，因为 HCC 往往对传统治疗方法有抵抗力，并且可能表现出攻击行为。标靶治疗、放射性碘治疗、手术和新型药物的应用对于控制这种疾病至关重要。最终用途范围主要包括医院、癌症治疗中心和专门从事肿瘤学的研究机构。

主要市场统计
基准年[2023] 64.4亿美元
预测年份 [2024] 68.2亿美元
预测年份 [2030] 99.6亿美元
复合年增长率（%） 6.41%

对肝细胞癌治疗市场的洞察揭示了几个关键的成长要素。甲状腺疾病盛行率的上升、分子诊断的进步以及健康意识的提高对市场的扩张做出了重大贡献。免疫疗法和标靶药物传递的最新发展显示出进一步增长的潜力。诊断影像技术的进步也增强了早期检测并促进及时介入。为了利用这些机会，相关人员应该投资个人化医疗研发，并与生技公司合作开发创新治疗方法。然而，市场面临治疗成本上升、专用药物供应有限以及对该疾病缺乏认识等挑战，这些都阻碍了市场的成长。

创新和研究应着重于精准医学的生物标记发现，从而提供量身定制的治疗方案并改善患者的治疗结果。包括新免疫疗法在内的联合治疗的开发可能是提高 HCC 疗效的有效方法。该市场竞争激烈但尚未开发，未满足的临床需求为进入市场提供了基础。公司可以透过进行全面的临床试验来检验新治疗方法，同时与医疗保健提供者密切合作以提高认知度和可及性，从而获得竞争优势。透过解决这些方面，公司可以在 Hürthle 细胞癌症治疗市场中建立更好的地位。

市场动态：针对快速发展的 Hürthle 细胞癌症治疗市场揭示的关键市场见解

Hürthle 细胞癌症治疗市场正因供需的动态交互作用而转变。了解这些不断变化的市场动态可以帮助组织做出明智的投资决策、改善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 甲状腺相关疾病增加
    • 提高有关治疗需求的医疗保健意识
    • 政府倡议增多
  • 市场限制因素
    • 缺乏治疗肝细胞癌的专家
  • 市场机会
    • 肝癌治疗技术开发
    • 活性化肝细胞癌治疗的研发
  • 市场挑战
    • 化疗的副作用和患者缺乏意识

波特五力：驾驭 Hürthle 细胞癌症治疗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解 Hürthle 细胞癌症治疗市场的外部影响

外部宏观环境因素在塑造 Hürthle 细胞癌症治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解 Hürthle 细胞癌症治疗市场的竞争状况

对 Hürthle 细胞癌症治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵 Hürthle 细胞癌治疗市场供应商的绩效评估

FPNV 定位矩阵是评估 Hürthle 细胞癌症治疗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划 Hürthle 细胞癌症治疗市场的成功之路

对 Hürthle 细胞癌症治疗市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监管核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 甲状腺相关疾病增加
      • 提高有关治疗需求的医疗保健意识
      • 政府加大力度
    • 抑制因素
      • 缺乏 HCC 治疗的熟练专业人员
    • 机会
      • 肝癌治疗技术进展
      • 扩大 HCC 治疗的研发活动
    • 任务
      • 化疗的副作用和患者缺乏意识
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 Hürthle 细胞癌治疗市场（依治疗）

  • 一般外科
  • 放射性碘
  • 机器人手术
  • 甲状腺全切除手术

第七章 Hürthle 细胞癌症治疗市场：依最终使用者分类

  • 门诊手术中心
  • 诊所
  • 医院

第八章北美和南美Hürthle细胞癌治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太地区Hürthle细胞癌治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第10章欧洲、中东和非洲的Hürthle细胞癌治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Agilent Technologies, Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Eli Lilly and Company
  • Eurofins Scientific SE
  • Illumina Inc.
  • Merck KGaA
  • Novartis AG
  • PerkinElmer, Inc.
  • Pfizer, Inc.
  • Provell Pharmaceuticals, LLC
  • Qiagen NV
  • Sanofi SA
  • Sorrento Therapeutics, Inc.
  • Teikoku Seiyaku Co. Ltd.
  • Thermo Fisher Scientific Inc.
Product Code: MRR-0355054AC4AC

The Hurthle Cell Carcinoma Treatment Market was valued at USD 6.44 billion in 2023, expected to reach USD 6.82 billion in 2024, and is projected to grow at a CAGR of 6.41%, to USD 9.96 billion by 2030.

Hurthle Cell Carcinoma (HCC) is a rare form of thyroid cancer that accounts for approximately 3-5% of differentiated thyroid cancers. The scope of research and treatment for HCC involves understanding its biological behavior, diagnosis, and effective therapeutic approaches. The necessity for innovative treatment options is critical due to HCC's tendency to resist traditional therapies and its potential for aggressive behavior. The application of targeted therapies, radioactive iodine treatment, surgery, and novel drugs are pivotal in managing the disease. The end-use scope primarily involves hospitals, cancer treatment centers, and research institutions dedicated to oncology.

KEY MARKET STATISTICS
Base Year [2023] USD 6.44 billion
Estimated Year [2024] USD 6.82 billion
Forecast Year [2030] USD 9.96 billion
CAGR (%) 6.41%

Insights into the HCC treatment market reveal several key growth factors. Rising prevalence of thyroid disorders, advancements in molecular diagnostics, and increased health awareness contribute significantly to market expansion. Recent developments in immunotherapy and targeted drug delivery present potential opportunities for further growth. Technological advancements in diagnostic imaging also enhance early detection, thereby facilitating timely intervention. To capitalize on these opportunities, stakeholders should invest in R&D for personalized medicine and partner with biotech firms to develop innovative therapies. However, the market faces challenges such as high treatment costs, limited availability of specialized drugs, and a lack of awareness about the disease, which can hinder growth.

Innovation and research should focus on biomarker discovery for precision medicine, which could lead to tailored treatment options and improved patient outcomes. The development of combination therapies that include emerging immunotherapy options might offer a viable approach to improve efficacy against HCC. The nature of the market is competitive yet underdeveloped, driven by unmet clinical needs, which presents a fertile ground for market entry. Companies can gain a competitive edge by pursuing comprehensive clinical trials to validate new treatments while working closely with healthcare providers to enhance awareness and accessibility. By addressing these aspects, firms can better position themselves in the market for Hurthle Cell Carcinoma treatments.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hurthle Cell Carcinoma Treatment Market

The Hurthle Cell Carcinoma Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing thyroid related diseases
    • Rising healthcare awareness about necessity of treatment
    • Increase in government initiatives
  • Market Restraints
    • Dearth of skilled professionals for the treatment of HCC
  • Market Opportunities
    • Technological developments in HCC treatment
    • Growing research and development activities of HCC treatment
  • Market Challenges
    • Adverse effects of the chemotherapy and lack of patient awareness

Porter's Five Forces: A Strategic Tool for Navigating the Hurthle Cell Carcinoma Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hurthle Cell Carcinoma Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hurthle Cell Carcinoma Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hurthle Cell Carcinoma Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hurthle Cell Carcinoma Treatment Market

A detailed market share analysis in the Hurthle Cell Carcinoma Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hurthle Cell Carcinoma Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hurthle Cell Carcinoma Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hurthle Cell Carcinoma Treatment Market

A strategic analysis of the Hurthle Cell Carcinoma Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hurthle Cell Carcinoma Treatment Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Agilent Technologies, Inc., AstraZeneca PLC, Bayer AG, Eli Lilly and Company, Eurofins Scientific SE, Illumina Inc., Merck KGaA, Novartis AG, PerkinElmer, Inc., Pfizer, Inc., Provell Pharmaceuticals, LLC, Qiagen N.V., Sanofi S.A., Sorrento Therapeutics, Inc., Teikoku Seiyaku Co. Ltd., and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Hurthle Cell Carcinoma Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment, market is studied across General Surgery, Radioactive Iodine, Robotic Surgery, and Total Thyroidectomy.
  • Based on End User, market is studied across Ambulatory Surgical Center, Clinic, and Hospital.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing thyroid related diseases
      • 5.1.1.2. Rising healthcare awareness about necessity of treatment
      • 5.1.1.3. Increase in government initiatives
    • 5.1.2. Restraints
      • 5.1.2.1. Dearth of skilled professionals for the treatment of HCC
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological developments in HCC treatment
      • 5.1.3.2. Growing research and development activities of HCC treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects of the chemotherapy and lack of patient awareness
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Hurthle Cell Carcinoma Treatment Market, by Treatment

  • 6.1. Introduction
  • 6.2. General Surgery
  • 6.3. Radioactive Iodine
  • 6.4. Robotic Surgery
  • 6.5. Total Thyroidectomy

7. Hurthle Cell Carcinoma Treatment Market, by End User

  • 7.1. Introduction
  • 7.2. Ambulatory Surgical Center
  • 7.3. Clinic
  • 7.4. Hospital

8. Americas Hurthle Cell Carcinoma Treatment Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Hurthle Cell Carcinoma Treatment Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Hurthle Cell Carcinoma Treatment Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Agilent Technologies, Inc.
  • 3. AstraZeneca PLC
  • 4. Bayer AG
  • 5. Eli Lilly and Company
  • 6. Eurofins Scientific SE
  • 7. Illumina Inc.
  • 8. Merck KGaA
  • 9. Novartis AG
  • 10. PerkinElmer, Inc.
  • 11. Pfizer, Inc.
  • 12. Provell Pharmaceuticals, LLC
  • 13. Qiagen N.V.
  • 14. Sanofi S.A.
  • 15. Sorrento Therapeutics, Inc.
  • 16. Teikoku Seiyaku Co. Ltd.
  • 17. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. HURTHLE CELL CARCINOMA TREATMENT MARKET RESEARCH PROCESS
  • FIGURE 2. HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. HURTHLE CELL CARCINOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. HURTHLE CELL CARCINOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HURTHLE CELL CARCINOMA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HURTHLE CELL CARCINOMA TREATMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY GENERAL SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY RADIOACTIVE IODINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY ROBOTIC SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TOTAL THYROIDECTOMY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM HURTHLE CELL CARCINOMA TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. HURTHLE CELL CARCINOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 103. HURTHLE CELL CARCINOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023